Login / Signup

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis post-liver transplant: a case series.

Hunter RaganElizabeth J BeckmanTaryn BomersbackJennifer HewlettLauren KormelinkJulie SafirsteinLaura ShanleyLisa Lubsch
Published in: Pediatric pulmonology (2021)
Initiation of elx/tez/iva in patients with CF who received a liver transplantation may be safe with clinical benefits. This article is protected by copyright. All rights reserved.
Keyphrases
  • cystic fibrosis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors